Loading
companiesCompany
Aptose Biosciences
Aptose is a San Diego and Toronto company developing tuspetinib, an oral kinase inhibitor acting on FLT3, SYK, JAK and other targets, for acute myeloid leukaemia in combination with venetoclax and azacitidine.
Also called: Aptose Biosciences Inc.Aptose
Overview
Aptose Biosciences, listed on Nasdaq and the Toronto exchange, develops kinase inhibitors for blood cancers. Its lead, tuspetinib (HM43239), licensed from Hanmi, inhibits FLT3, SYK, JAK1/2 and other kinases and is being combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukaemia after single-agent responses in relapsed disease; an earlier candidate, luxeptinib, was deprioritised. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
San Diego, CA, US
Scorecard
All companies#89of 1244 companies, score 53
- approved products +12
- phase 1/2 +1
- targets +2
- modalities +2
- regions +6
- registry trials +30
2 approved, 0 in phase 3, 1 earlier, 1 targets, 1,414 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedSmall-molecule BCL-2 inhibitor
Venetoclax · Venclexta
A pill that removes the survival shield from leukaemia cells, enabling chemotherapy-free, time-limited treatment for CLL.
ApprovedSmall-molecule hypomethylating agent (cytotoxic)
Azacitidine · Vidaza / Onureg (oral)
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Phase 2Oral kinase inhibitor
Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.
Similar pages
- TrialStudy of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- TrialStudy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- TargetProtein kinase C family (PKC)
Shares FLT3, Acute myeloid leukaemia.
- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- PersonHartmut Döhner
Shares FLT3, Acute myeloid leukaemia.
- TrialStudy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
cancers
fronts
targets
drugs
ApprovedSmall-molecule hypomethylating agent (cytotoxic)
Azacitidine · Vidaza / Onureg (oral)
Phase 2Oral kinase inhibitor
ApprovedSmall-molecule BCL-2 inhibitor
Venetoclax · Venclexta